Our Team

At NodThera, our mission is to treat chronic disease by targeting inflammation at its source. 

We are pursuing this mission at a time of growing awareness about the revolutionary potential of the NLRP3 inflammasome. Supported by blue-chip investors and led by a management team with a proven track record in drug discovery and development, NodThera is pushing the science of NLRP3 inflammasome inhibition into new frontiers.

Leadership

Adam
katina dolton 121420 342x342 v02a
Alan
Donald Johns cropped
Allison
Chris
Mark
nick

Board

Investors